Skip to main content
SpringerLink
Log in

New immunosuppressants: mycophenolate mofetil and 15-deoxyspergualin

  • Chapter
Disease-modifying Therapy in Vasculitides

Part of the book series: Progress in Inflammation Research ((PIR))

Abstract

Primary or idiopathic vasculitic syndromes are a group of inflammatory disorders of presumed autoimmune origin characterized by inflammation of blood vessels leading to vessel wall necrosis and (partial) obliteration or thrombosis of the vascular lumen. Clinical signs and symptoms are caused by disruption of adequate macro-and microcirculatory blood flow of organs or tissues by the vascular inflammatory proces. The classification of these idiopathic systemic vasculitic syndromes is based on the size and localization of the vessels predominantly involved and certain characteristics of the histopathology of the inflammatory process [1]. Several different classification schemes have been proposed, the latest modification being the scheme set up by a Consensus Conference in Chapel Hill in 1992 (Tab. 1) [2]. The factors involved in the pathogenesis of primary vasculitides are as yet unidentified. The possible autoimmune origin of these diseases is supported by the strong association of the presence of autoantibodies directed against neutrophil cytoplasmic antigens, so-called anti-neutrophil cytoplasmic antibodies (ANCA), in some of the primary small vessel vasculitides [2, 3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fauci AS, Haynes BF, Katz P (1978) The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 89: 660–676

    PubMed  CAS  Google Scholar 

  2. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CGM et al (1994) Nomenclature of systemic vasculitides. Proposal of an International Consensus Conference. Arthritis Rheum 37: 187–192

    PubMed  CAS  Google Scholar 

  3. Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW (1994) Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 46: 1–15

    PubMed  CAS  Google Scholar 

  4. Evans J, Hunder GG (1998) Polymyalgia rheumatica and giant cell arteritis. Clin Geriatr Med 14: 455–473

    PubMed  CAS  Google Scholar 

  5. Rai A, Nast C, Adler S (1999) Henoch-Schönlein purpura nephritis. J Am Soc Nephrol 10: 2637–2644

    CAS  Google Scholar 

  6. Guillevin L, Lhote F (1998) Treatment of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 41: 2100–2105

    PubMed  CAS  Google Scholar 

  7. Guillevin L (1999) Treatment of classic polyarteritis nodosa in 1999. Nephrol Dial Transplant 14: 2077–2079

    PubMed  CAS  Google Scholar 

  8. Leung DY, Schlievert PM, Meissner HC (1998) The immunopathogenesis of Kawasaki syndrome. Arthritis Rheum 41: 1538–1547

    PubMed  CAS  Google Scholar 

  9. aupland KB, Dele Davies H (1999) Epidemiology, etiology, and management of Kawasaki’s disease. State of the art. Pediatr Cardiol 20: 177–183

    Google Scholar 

  10. Fauci AS, Katz P, Haynes BF, Wolff SM (1979) Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301: 235–238

    PubMed  CAS  Google Scholar 

  11. Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener’s Granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 76–85

    PubMed  CAS  Google Scholar 

  12. Jennette JC, Falk RJ (1997) Small-vessel vasculitis. N Engl J Med 337: 1512–1523

    CAS  Google Scholar 

  13. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 116: 488–498

    PubMed  CAS  Google Scholar 

  14. Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, Emery P, Howie AJ, Bacon PA (1993) Relapses in patients with a systemic vasculitis. Q J Med 86: 779–789

    CAS  Google Scholar 

  15. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119: 366–369

    PubMed  CAS  Google Scholar 

  16. Masala A, Faedda R, Alagna S, Satta A, Chiarelli G, Rovasio PP, Ivaldi R, Taras MS, Lai E, Bartoli E (1997) Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 126: 292–295

    PubMed  CAS  Google Scholar 

  17. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC (1998) Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med 129: 49–58

    PubMed  CAS  Google Scholar 

  18. Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger Jr TA, Kwoh CK (1995) Effects of cyclophosphamide on the development of malignancy and on long term survival of patients with rheumatoid arthritis. Arthritis Rheum 38: 1120–1127

    PubMed  CAS  Google Scholar 

  19. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener’s granulomatosis. Ann Intern Med 124: 477–484

    PubMed  CAS  Google Scholar 

  20. Westman KWA, Bygren PG, Olsson H, Ranstam J, Wieslnader J (1998) Relapse rate, renal survival and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9: 842–852

    CAS  Google Scholar 

  21. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, Michael J, Savage COS, Bacon P (1997) Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med 90: 401–409

    CAS  Google Scholar 

  22. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, Lesavre Ph, Jacquot C, Bindi P, Bielefeld P et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40: 2187–2198

    PubMed  CAS  Google Scholar 

  23. Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement. A prospective, randomized study. Arthritis Rheum 41: 1835–1844

    PubMed  CAS  Google Scholar 

  24. de Groot K, Adu D, Savage COS (2000) To pulse or not to pulse in ANCA-associated vasculitis – a critical analysis. Clin Exp Immunol 120 (Suppl 1): 68

    Google Scholar 

  25. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS (1995) An analysis of forty-two Wegener’s granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38: 608–613

    PubMed  CAS  Google Scholar 

  26. De Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross WL (1998) Induction of remission in Wegener’s granulomatosis with low dose methotrexate. J Rheumatol 25: 492–495

    PubMed  Google Scholar 

  27. Stone JH, Tun W, Hellman DB (1999) Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 26: 1134–1139

    PubMed  CAS  Google Scholar 

  28. Reinhold-Keller E, de Groot K, Rudert H, Nölle B, Heller M, Gross WL (1996) Response to trimethoprim/sulfamethoxazole in Wegener’s granulomatosis depends on the phase of the disease. Q J Med 89: 15–23

    CAS  Google Scholar 

  29. Jayne DRW, Gaskin G (EUVAS) (1999) Randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated vasculitis (CYCAZAREM). J Am Soc Nephrol 10: 105A

    Google Scholar 

  30. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Gross WL (1996) Therapy for maintenace of remission in sixty-five patients with generalized Wegener’s granulomatosis. Methotrexate versus trimethoprim-sulfamethoxazole. Arthritis Rheum 39: 2052–2061

    PubMed  Google Scholar 

  31. Haubitz M, Koch KM, Brunkhorst R (1998) Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 13: 2074–2076

    PubMed  CAS  Google Scholar 

  32. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM (1996) Trimethoprimsulfamethoxazole for the prevention of relapses of Wegener’s granulomatosis. N Engl J Med 335: 16–20

    PubMed  CAS  Google Scholar 

  33. Pedersen RS, Bistrup C (1996) Etoposide: more effective and less bone-marrow toxic than standard immunosuppressive therapy in systemc vascilitis? Nephrol Dial Transplant 11: 1121–1123

    PubMed  CAS  Google Scholar 

  34. Takeuchi T, Linuma H, Kunimoto S, Masuda T, Ishizuka M, Takeuchi M, Hamada M, Naganawa H, Kondo S, Umezawa H (1981) A new antitumor antibiotic, spergualin: Isolation and antitumor activity. J Antibiot 34: 1619

    PubMed  CAS  Google Scholar 

  35. Maeda K, Umeda Y, Saino T (1993) Synthesis and background chemistry of 15 deoxyspergualin. Ann NY Acad Sci 685: 123–135

    PubMed  CAS  Google Scholar 

  36. Nishikawa K, Shibasaki C, Takahashi K, Nakamura T, Takeuchi T, Umezawa H (1986) Antitumor activity of spergualin: a novel antitumor antibiotic. J Antibiot 39: 1461–1466

    PubMed  CAS  Google Scholar 

  37. Muindi JF, Lee SJ, Baltzer L, Jakubowski A, Scher HI, Sprancmanis LA, Riley CM, Van der Velde D, Young CW (1991) Clinical pharmacology of deoxyspergualin in patients with advanced cancer. Cancer Res 12: 3096

    Google Scholar 

  38. Thies J, Walter P, Zimmermann F, Dickneite G, Sedlacek H, Keller H, Feifel G (1987) Prolongation of graft survival in allogenic pancreas and liver transplantation by 15 eoxyspergualin. Eur Surg Res 19: 129–134

    PubMed  CAS  Google Scholar 

  39. Dickneite G, Schorlemmer H, Weinmann E, Bartlett R, Sedlacek H (1987) Skin transplantation in rats and monkeys: Evaluation of efficient treatment with 15-deoxyspergualin. Transplant Proc 19: 4244–4247

    PubMed  CAS  Google Scholar 

  40. Reichenspurner H, Hildebrandt A, Human PA, Boehm DH, Rose AG, Odell JA, Reichart B, Schorlemmer H (1990) 15-Deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates. Transplantation 50: 181–185

    PubMed  CAS  Google Scholar 

  41. Engemann R, Gassell HJ, Lafrenz E, Stoffregen C, Thiede A (1987) Transplantation tolerance after short-term administration of 15-deoxyspergualin in orthotopic rat liver transplantation. Transplant Proc 19: 4241–4243

    PubMed  CAS  Google Scholar 

  42. Fukao K, Otsuka M, Iwashaki H, Yuzawa K, Iwasaki Y (1989) Immunosuppressive effect of deoxyspergualin on acute renal allograft rejection in dogs. Transplant Proc 21: 1090–1093

    PubMed  CAS  Google Scholar 

  43. Nicolic-Patterson DJ, Kerr PG, Lan HY, Tesch GH, Atkins RC. Deoxyspergualin: A new immunosuppressive drug for the treatment of auto-immune disease. Nephron 1995; 70: 391–396

    Google Scholar 

  44. Fujii H, Takada T, Nemoto K, Yamashita T, Abe F, Fujii F, Takeuchi T (1990) Deoxyspergualin directly suppresses antibody formation in vivo and in vitro. J Antibiot 43: 213–219

    CAS  Google Scholar 

  45. Makino M, Fujiwara M, Watanabe H, Aoyagi T, Umezawa H (1987) Immunosuppressive activities of deoxyspergualin. II. The effect of the antibody responses. Immunopharmacol 14: 115–122

    CAS  Google Scholar 

  46. Tepper MA, Petty B, Bursuker I, Pasternak RD, Cleaveland J, Spitalny GL, Schacter B Inhibition of antibody production by the immunosuppressive agent, 15-deoxyspergualin. Transplant Proc 23: 328–331

    Google Scholar 

  47. Tepper M, Nadler S, Mazzucco C, Singh C, Kelley S (1993) Mechanism of action of 15deoxyspergualin, a novel immunosuppressive drug. Ann NY Acad Sci 685: 122–135

    Google Scholar 

  48. Investigation Report Form of the Results of Use to the Ministry of Health and Welfare, Nippon Kayaku Co. Ltd., 1998

    Google Scholar 

  49. Fujii H, Takada H, Kyuichi T, Fuminori N, Fujii A, Talmadge A, Takeuchi J (1992) Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activation in vitro. Int J Immunopharmacol 14: 731–737

    CAS  Google Scholar 

  50. Odaka C, Toyoda E, Nemoto K (1998) Immunosuppressant deoxyspergualin induces apoptotic cell death in dividing cells. Immunology 95: 370–376

    PubMed  CAS  Google Scholar 

  51. Morikowa K, Oseko F, Moridawa S (1992) The suppressive effect of deoxyspergualin on the differentiation of human B lymphocytes maturating into immunoglobulin-producing cells. Transplantation 54: 526–531

    Google Scholar 

  52. Sterbenz KG, Tepper MA (1994) The effect of 15-deoxyspergualin on antibody secretion from antibody producing B-cell hybridomas and myelomas. Transplant Proc 26: 3218

    PubMed  CAS  Google Scholar 

  53. Tepper MA, Nadler SG, Esselstyn J, Sterbenz C (1995) Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide induced NFkappaB activation. J Immunol 155: 2427–2436

    PubMed  CAS  Google Scholar 

  54. Wang B, Benoist C, Mathis D (1996) The immunosuppressant 15-deoxyspergualin reveals commonality between PreT and PreB cell differentiation. J Exp Med 183: 2427–2436

    PubMed  CAS  Google Scholar 

  55. Dickneite G, Schorlemmer HU, Sedlacek HH (1987) Decrease of mononuclear phagocyte cell functions and prolongation of graft survival in experimental transplantation by 15-deoxyspergualin. Int J Immunopharmacol 9: 559–565

    PubMed  CAS  Google Scholar 

  56. Takasu S, Sakagami K, Morisaki F, Kawamura T, Haisa M, Oiwa T, Inagaki M, Hasuoka H, Kurozumi Y, Orita K (1991) Immunosuppressive mechanism of 15-deoxyspergualin on sinusoidal lining cells in swine liver transplantation: suppression of MHC class II antigens and interleukin-1 production. J Surg Res 51: 165–169

    PubMed  CAS  Google Scholar 

  57. Kerr PG, Nikolic-Paterson DJ, Lan HY, Rainone S, Tesch G, Atkins RC (1994) Deoxyspergualin suppresses local macrophage proliferation in renal allograft rejection. Transplantation 58: 596–601

    PubMed  CAS  Google Scholar 

  58. Hoeger P, Tepper MA, Faith A, Higgins J, Lamb J, Geha R (1994) The immunosuppressant deoxyspergualin inhibits antigen processing in monocyts. J Immunol 153: 3908–3916

    PubMed  CAS  Google Scholar 

  59. Nadler SG, Tepper MA, Schacter B, Mazzucco CE (1994) Interaction of the immunosuppressant deoxyspergualin with a member of the HSP 70 family of heat shock proteins. Science 258: 484–486

    Google Scholar 

  60. Nadeau K, Nadler SG, Saulnier M, Tepper MA, Walsh CT (1994) Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry 33: 2561–2567

    PubMed  CAS  Google Scholar 

  61. Smith DV, Whitesell L, Katsanis E (1998) Molecular chaperones: Biology and prospects for pharmacological intervention. Pharmacol Rev 4: 493–513

    Google Scholar 

  62. DeNagel DC, Pierce SK (1993) Heat shock proteins in immune responses. Crit Rev Immunol 13: 71–81

    PubMed  CAS  Google Scholar 

  63. Tepper MA (1996) In vitro pharmacology, mechanism of action and preclinical pharmacokinetics and toxicology of DSG. In: R Lieberman, A Mukherjee (eds): Principles of drug development in transplantation and autoimmunity. RG Landes Company, London, 383–388

    Google Scholar 

  64. Gore PF (1996) Deoxyspergualin: clinical experience. Transplant Proc 2: 871–872

    Google Scholar 

  65. Ohlman S, Zilg H, Schindel F, Lindholm A (1994) Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. Transpl Int 1: 5–10

    Google Scholar 

  66. Pilot study phase I study of gusperimus in rheumatoid arthritis, Bristol-Myers Squibb Pharmaceutical Research Institute, 1995

    Google Scholar 

  67. Pilot study phase I study of gusperimus in multiple sclerosis, Bristol-Myers Squibb Pharmaceutical Research Institute, 1993

    Google Scholar 

  68. Comparison of pharmacokinetics in Caucasians and Japanese, Behringwerke AG, 1993

    Google Scholar 

  69. Havlin KA, Kuhn JG, Koeller J, Boldt DH, Craig JB, Brown TD, Weiss GR, Cagnola J, Phillips J, Harman G et al (1995) Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study. Anticancer Drugs 2: 229–236

    Google Scholar 

  70. Ronneberger H (1994) Pharmacological-toxicological expert opinion on immodul. Behringwerke AG

    Google Scholar 

  71. Ramos EL, Nadler SG, Grasela DM, Kelley SL (1996) Deoxyspergualin: mechanism of action and pharmacokinetics. Transplant Proc 2: 873–875

    Google Scholar 

  72. Ohlman S, Zilg H, Schindel F, Lindholm A (1994) Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. Transplant Int 7:5–10

    CAS  Google Scholar 

  73. Single dose safety, tolerance and pharmacokinetics of subcutaneous administration of gusperimus in healthy subjects, Bristol-Myers Squibb Pharmaceutical Research Institute, 1994

    Google Scholar 

  74. Phase I study of subcutaneous gusperimus in patients with rheumatoid arthritis, Bristol-Myers Squibb Pharmaceutical Research Institute, 1996

    Google Scholar 

  75. Micronucleus test using mice treated with NKT-01 (N40), June 29, 1987, report of Nippon Kayaku, Japan

    Google Scholar 

  76. Intravenous micronucleus study in rats, Bristol-Myers Squibb Pharmaceutical Research Institute, 1994

    Google Scholar 

  77. Mutagenicity study of NKT-01 using microorganisms, Sogo Biomedical Laboratories, 1986

    Google Scholar 

  78. Chromosome aberration study of NKT-01 using mammal cultivated cells, Sogo Biomedical Laboratories, 1986

    Google Scholar 

  79. In vitro mammalian cytogenetic test in cultured human lymphocytes, CIT, 1993

    Google Scholar 

  80. Ames reverse-mutation study in Salmonella and Escherichia coli, Bristol-Myers Squibb Pharmaceutical Research Institute,1993

    Google Scholar 

  81. Ames/Salmonella microbial mutagenicity study including Escherichia coli WP2 uvrA, Bristol-Myers Squibb Pharmaceutical Research Institute, 1993

    Google Scholar 

  82. Chromosome aberration study in cultured mammalian (CHL) cells, Bristol-Myers Squibb Pharmaceutical Research Institute,1993

    Google Scholar 

  83. Cytogenetics study in primary human lymphocytes, Bristol-Myers Squibb Pharmaceutical Research Institute,1993

    Google Scholar 

  84. The effect of i.v. injection of NKT-01 on rats during the period of fetal organogenesis (segment II), Nihon Bioresearch center, 1986

    Google Scholar 

  85. Teratogenicity study of NKT-01 in rabbits (intravenous administration), Nippon Kayaku, 1991

    Google Scholar 

  86. Segment II intravenous teratology study in rats with an evaluation of postnatal development, Bristol-Myers Squibb Pharmaceutical Research Institute,1993

    Google Scholar 

  87. Segment II intravenous teratology study in rabbits, Bristol-Myers Squibb Pharmaceutical Research Institute,1993

    Google Scholar 

  88. Segment III intravenous perinatal/postnatal study in rats, Bristol-Myers Squibb Pharmaceutical Research Institute, 1993

    Google Scholar 

  89. One-year intraperitoneal toxicity study in rats with a nine-week recovery period, Bristol-Myers Squibb Pharmaceutical Research Institute, 1993

    Google Scholar 

  90. Prospective, placebo-controlled, randomized, double-blind multicentre Phase III in patients suffering from multiple sclerosis, Behringwerke AG, 1996

    Google Scholar 

  91. Thomas FT, Tepper MA, Thomas JM, Haisch CE (1993) 15-Deoxyspergualin: a novel immunosuppressive drug with clinical potential. Ann NY Acad Sci 685: 172–195

    Google Scholar 

  92. Okubo M, Tamura K, Kamata K, Tsukamoto Y, Nakayama Y, Osakabe T, Sato K, Go M, Kumano K, Endo T (1993) 15-deoxyspergualin “rescue therapy” for methylprednisolone-resistant rejection of renal transplants as compared with anti-T cell monoclonal antibody (OKT3). Transplantation 55: 505–508

    PubMed  CAS  Google Scholar 

  93. Miura s, Okazaki H, Sato T, Amada N, Sakurada M (1997) Succesful renal transplantation in presensitized recipients with double-filtration plasmapheresis and 15deoxyspergualin. Transplant Proc 29: 350–351

    PubMed  CAS  Google Scholar 

  94. Takahashi K, Yagisawa T, Sonda K, Kawaguchi Y, Yamaguchi H, Toma H, Agishi T, Ota K (1993) ABO-incompatible kidney transplantation in a single-center trial. Transplant Proc 1: 271–273

    Google Scholar 

  95. Groth CG, Ohlman S, Ericzon BG, Barkholt L, Reinholt FP (1990) Deoxyspergualin for liver graft rejection. Lancet 336: 626

    PubMed  CAS  Google Scholar 

  96. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper MA, Grasela D, Buzdar A, Valero V et al (1995) Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 14: 3030–3067

    Google Scholar 

  97. Birck R, Nowack R, Drexler JM, Hotta O, Goebel, van der Woude FJ (1999) 15-Deoxyspergualin induces remission in Wegener’s Granulomatosis: report of three cases. [Abstract] J Am Soc Nephrol 11: 154A

    Google Scholar 

  98. Hotta O, Ito K, Furuta T, Chiba S, Taguma Y (1999) Effects of deoxyspergualin on proliferative glomerulonephritis. Nippon Jinzo Gakkai Shi 1:21–8

    Google Scholar 

  99. Nelson P, Eugui E, Allison AC (1990) Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. J Med Chem 33: 833–838

    PubMed  CAS  Google Scholar 

  100. Lee W, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH (1990) Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 7: 161–166.

    PubMed  CAS  Google Scholar 

  101. Eugui EM, Alquist SJ, Muller CD, Allison AC (1991) Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 33: 161–173

    PubMed  CAS  Google Scholar 

  102. Allison AC, Eugui EM (1996) Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 10: 77–84

    PubMed  CAS  Google Scholar 

  103. Allison AC, Eugui EM (1993). Immunosuppressive and other effects of mycophenolic acid and ester prodrug, mycophenolate mofetil. Immunol Rev 136: 5–28

    PubMed  CAS  Google Scholar 

  104. Natsumeda Y, Carr SF (1993). Human type I and type II IMP dehydrogenase as targets. Ann NY Acad Sci 696: 88–93

    PubMed  CAS  Google Scholar 

  105. Dayton J, Lindsten T, Thompsom CB, Mitchell BS (1994) Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol 52: 984–991

    Google Scholar 

  106. Bullingham R, Monroe S, Nicholls A, Hale M (1996) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36: 315–324

    PubMed  CAS  Google Scholar 

  107. Bullingham RES, Nicholls A, Hale M (1996) Pharmacokinetics of mycophenolate mofetil (RS 61443): a short review. Transplant Proc 28: 925–929

    PubMed  CAS  Google Scholar 

  108. Sham LM, Nowak I (1995) Mycophenolic acid: measurement and relationship to pharmacological effects. Ther Drug Monit 17: 690–699

    Google Scholar 

  109. Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348: 1357–1359

    PubMed  CAS  Google Scholar 

  110. Nowak I, Shaw LM (1995) Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41: 1011–1017

    PubMed  CAS  Google Scholar 

  111. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM (1998) Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 65: 1127–1129

    PubMed  CAS  Google Scholar 

  112. Epinette WW, Parker CM, Jones EL, Greist MC (1987) Mycophenolic acid for psoriasis. J Am Acad Dermatol 17: 962–971

    CAS  Google Scholar 

  113. European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321–1325

    Google Scholar 

  114. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225–232.

    Google Scholar 

  115. Tricontinental Mycophenolate Mofetil Renal Transplant Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029–1037

    Google Scholar 

  116. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C, for the International Mycophenolate Mofetil Renal Transplant Study Groups (1997) Mycophenolate mofetil in renal allograft recipients. A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 63: 39–47

    Google Scholar 

  117. Mathew T, for the Tricontinental Mycophenolate Mofetil Renal Transplant Study Group (1998) A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Results at three years. Transplantation 65: 1450–1454

    Google Scholar 

  118. Kim YS, Moon JI, Kim SI, Park K (1999) Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantation. Transplantation 68: 578–581

    PubMed  CAS  Google Scholar 

  119. Van Bruggen MCJ, Walgreen B, Rijke TPM, Berden JHM (1998) Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 9: 1407–1415

    Google Scholar 

  120. Jonsson CA, Svensson L, Carlsten H (1999) Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLIpr/lpr mice. Clin Exp Immunol 116: 534–541

    PubMed  CAS  Google Scholar 

  121. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A (1999) Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10: 1542–1549

    PubMed  CAS  Google Scholar 

  122. Adams PL, Iskandar SS, Rohr MS (1999) Biopsy-proven resolution of immune complex-mediated crescentic glomerulonephritis with mycophenolate mofetil therapy in an allograft. Am J Kidney Dis 33: 552–554

    PubMed  CAS  Google Scholar 

  123. Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ (1999) Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 40: 265–268

    PubMed  CAS  Google Scholar 

  124. Enk AH, Knop J (1999) Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 135: 54–56

    PubMed  CAS  Google Scholar 

  125. Grundmann-Kollmann M, Kaskel P, Leiter U, Krahn G, Ralf S, Peter U, Kerscher M (1999) treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 135: 724–725

    PubMed  CAS  Google Scholar 

  126. Altschuler EL (1999) Mycophenolate mofetil for primary biliary cirrhosis and sclerosing cholangitis? Nephrol Dial Transplant 14: 798–799

    PubMed  CAS  Google Scholar 

  127. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Zum Buschenfelde K-HM, Schlaak JF (1999) Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 44: 625–628

    PubMed  CAS  Google Scholar 

  128. Present DH (1999) Is mycophenolate mofetil a new alternative in the treatment of inflammatory bowel disease? Gut 44: 592–593

    PubMed  CAS  Google Scholar 

  129. Nowack R, Birck R, van der Woude FJ (1997) Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 349: 774

    PubMed  CAS  Google Scholar 

  130. Briggs WA, Choi MJ, Scheel PJ Jr, Kiberd B, MacDonald A (1998) Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31: 213–217

    PubMed  CAS  Google Scholar 

  131. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA (1999) Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 10: 833–839

    PubMed  CAS  Google Scholar 

  132. Hauser IA, Sterzel RB (1999) Mycophenolate mofetil: therapeutic applications in kidney transplanation and immune-mediated renal disease. Curr Opin Nephrol Hypertens 8: 1–6

    PubMed  CAS  Google Scholar 

  133. Gross WL (1999) New concepts in treatment protocols for severe systemic vasculitis. Curr Opin Rheumatol 11: 41–46

    PubMed  CAS  Google Scholar 

  134. Jayne DRW (1999) Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens 8: 563–567

    PubMed  CAS  Google Scholar 

  135. Daina E, Schieppati A, Remuzzi G (1999) Mycophenolate mofetil for the treatment of Takayashu arteritis: report of three cases. Ann Intern Med 130: 422–426

    PubMed  CAS  Google Scholar 

  136. Waiser J, Budde K, Braasch E, Neumayer HH (1999) Treatment of c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis 34: e9 (http://www.ajkd.org)

    PubMed  CAS  Google Scholar 

  137. Haidinger M, Neumann I, Jäger H, Grützmacher H, Bayer P, Meisl FTh (2000) Mycophenolate mofetil treatment of ANCA-associated small-vessel vasculitis: a pharmacokinetically controlled study. Clin Exp Immunol 120 (Suppl 1): 72

    Google Scholar 

  138. Nachman PH, Joy MS, Hogan SL, Jennette JC, Falk RJ (2000) Mycophenolate mofetil: reliminary results of a feasibility trial in relapsing ANCA small vessel vasculitis. Clin Exp Immunol 120 (Supp1.1): 72

    Google Scholar 

  139. Pesavento TE, Falkenhain ME, Rovin BH, Hebert LA (1999) Mycophenolate mofetil in anti-neutrophil cytoplasmic antibody vasculitis. J Am Soc Nephrol 10: 114A

    Google Scholar 

  140. Stegeman CA, Cohen Tervaert JW (2000) Mycophenolate mofetil for remission induction in patients with active Wegener’s granulomatosis intolerant to cyclophosphamide. J Am Soc Nephrol 11: 98A

    Google Scholar 

  141. Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ (1999) Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10:1965–1971

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Nephrology, University Hospital Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands

    Coen A. Stegeman & Rainer Birck

Authors
  1. Coen A. Stegeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rainer Birck
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Clinical Immunology, University Hospital Groningen, P.O. Box 30.001, Groningen, 9700 RB, The Netherlands

    Cees G. M. Kallenberg

  2. Department of Clinical and Experimental Immunology, University Hospital Maastricht, P.O. Box 5800, Maastricht, 6202 AZ, The Netherlands

    Jan W. Cohen Tervaert

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Basel AG

About this chapter

Cite this chapter

Stegeman, C.A., Birck, R. (2001). New immunosuppressants: mycophenolate mofetil and 15-deoxyspergualin. In: Kallenberg, C.G.M., Tervaert, J.W.C. (eds) Disease-modifying Therapy in Vasculitides. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8235-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8235-4_7

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9485-2

  • Online ISBN: 978-3-0348-8235-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation